London, UK, 18 April 2018

Dr Jan Petracek selected as one of the winners of the 2018 DIA Inspire Award

London, UK18 April 2018: Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce that Chief Operating Officer and PrimeVigilance CEO, Dr Jan Petracek will receive the DIA Inspire Award for the EMEA Region during the upcoming DIA EuroMeeting…

London, UK, 11 April 2018

Unaudited Preliminary Results for the year ended 31 December 2017

  • Net service revenue growth of 36% driving total revenue growth of 21%
  • Within services, Drug Safety & Medical Information (pharmacovigilance) revenue grew 67%
  • New business won in 2017 increased 29% to £54 million with a contracted backlog at 1 January 2018 of £88 million
  • Positive PeproStat Phase II results
  • Corporate strategy refined to…

London, UK, and Hoofddorp, The Netherlands, 28 February 2017

PSR Orphan Experts, Ergomed’s rare disease specialist division, organises fundraiser to support Global Rare Disease Day® 2018

– Beach volleyball event to raise funds for children suffering from epidermolysis bullosa, a partly hereditary orphan incurable skin condition –

London, UK, and Hoofddorp, The Netherlands – 28 February 2018: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a specialised pharmaceutical services and drug development company, together with its rare disease subsidiary PSR Group…

London, UK, December 15, 2017

Ergomed Announces Board Changes: Stephen Stamp appointed as CEO and Jan Petracek as COO

London, UK – 15 December 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a specialised pharmaceutical services and drug development company, today announces changes to its Board and management team with the appointment of Stephen Stamp as Chief Executive Officer and Dr Jan Petracek as Chief Operating Officer and a Board Director of…

London, UK, 12 December 2017

Ergomed expands its co-development pipeline with a multi-product partnership with Allergy Therapeutics for oral allergy immunotherapies

  • Ergomed to receive future tiered royalties for each product in addition to service fees
  • Further contribution to service growth plus upside from sustainable drug development
  • Ergomed’s extensive experience in conducting trials in allergy therapies led to new co development deal

London, UK – 12 December 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a…

Page 1 of 1912345...10...Last »
Translate »